While most states are in a race to stimulate their economy by throwing hundreds of thousands and even billions of dollars into unethical and unproven research involving the use and destruction of human life the market for adult stem cells is multiplying rapidly and investors are taking notice. From the Chicago Tribune:
A gathering known as the Stem Cell Summit might sound so controversial it would need a steely moderator, or even police protection, so politically delicate is the science of using embryos in medical research.
But this affair at the Hilton New York on Sixth Avenue in Manhattan was all business because while the research community remains interested in embryonic stem cells, these days the focus is on the potential uses of adult stem cells, where it turns out that significant progress is being made away from the political spotlight.
Progress that is helping human patients in several clinical trials today:
“About 11,000 people have been treated in the U.S. with stem cell products in the last two years,” Robin Young, a financial analyst who follows the stem cell industry, told more than 250 institutional investors and Wall Street firm representatives at the summit in New York last month. “Virtually all of the therapeutic stem cells that are or will soon be commercialized are adult stem cells,” Young said.
Yes, the United States is treating patients with stem cells, isn’t that the goal of stem cell research?:
“One of the pieces of rhetoric you hear all of the time is that the U.S. is far behind in stem cell research because of this or that but the fact is, we are not only the furthest along in the U.S., but the world,” said Randal Mills, chief executive of Osiris Therapeutics Inc., who some call the Bill Gates of the stem cell industry…
“We are practicing cellular therapy today and people wouldn’t be alive if it were not for these therapies,” said Kenneth Giacin, chief executive of StemCyte, which manages a cord blood cell bank and database for patients needing a transplant.
Not only that, but the ACS research business is booming. Osiris’ Osteocel, which is a bone marrow treatment that stimulates bone growth, saw their sales jump 83% in the last year and StemCyte Inc. is seeing its revenue grow 50 to 70 percent annually.
We may not exactly be “leading the world” in ASC research as Mr. Mills suggests, there are still plenty of people leaving the country such treatments. But more and more American scientists and investors are picking up on this truly life saving area of research and successfully working together to fund and discover new uses for these amazing stem cells. If only our politicians and news media would pay attention and let go of their obsession with research that destroys human life with little to no progress to show for itself.
Read more about these and other stem cell companies and their plans for future clinical trials to develop treatments for heart failure and breast reconstructive surgery.
ABC News Medical Minute: Stem Cell Research Grows Up (video)
“A Cellular Approach”
ASC vs. ESC research scorecard
Umbilical Cord Blood Stem Cells Help Brain Function in Mice
States Take Sides on Stem Cell Research